Tours Cedex 9

• EPIK-P4: A Phase II single-arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patien … Recruiting
  2024-519960-42-00 4 2025-12-11 PIK3CA-Related Overgrowth Spectrum (PROS)
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting
  2025-521710-25-00 4 2025-12-04 Lewy Body Dementia Psychosis (LBDP)
• CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the … Recruiting
  2023-508861-34-00 9 2025-12-02 Pneumocystis pneumonia
• Momelotinib in VEXAS syndrome Recruiting
  2024-519779-24-00 4 2025-11-25 VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC) syndr
• Interest of early erectile rehabilitation with Sildenafil after proctectomy for rectal cancer : Randomized controlled trial (RECTIL) Recruiting
  2024-515431-30-00 5 2025-08-14 Men treated with proctectomy for rectal cancer
• A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit … Recruiting
  2024-517247-31-00 5 2025-07-07 Newly Diagnosed Higher Risk Myelodysplastic Syndrome
• Evaluating ivonescimab as a potential treatment for pleural mesothelioma patients whose cancer has returned after previous immunotherapy and … Recruiting
  2024-519052-82-00 4 2025-06-30 pleural mesothelioma
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Intra-arterial thrombolysis after SUCCESSful reperfusion of acute ischemic stroke Recruiting
  2023-506935-14-01 5 2025-06-01 Ischemic stroke
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-re … Recruiting
  2024-516650-22-00 6 2025-05-16 Renal carcinoma
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi … Recruiting
  2024-515593-27-00 5 2025-05-08 relapsed or refractory mantle cell lymphoma (R/R MCL)
• Evaluation of the benefits of Administering immunosuppressive drugs as Single daily doses over the first Year after liver transplantation Recruiting
  2023-506601-19-00 6 2025-04-15 transplantation
• A Study to Understand the Optimization of the Cytokine Release Syndrome Profile for Glofitamab along with Gemcitabine Plus Oxaliplatin in Pa … Recruiting
  2024-516791-15-00 4 2025-04-08 Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
• A multicenter, single-arm, open-label study to evaluate efficacy and safety of switching from anti-C5 antibody treatment to iptacopan treatm … Recruiting
  2023-504550-35-00 5 2025-04-03 Atypical Hemolytic Uremic Syndrome (aHUS)
• Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastat … Recruiting
  2023-507873-16-00 11 2025-03-04 1st line treatment for unresectable metastatic colorectal cancer
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-509787-15-00 5 2025-02-17 Patients with localised prostate cancer and high-risk features of rela
• DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI … Recruiting
  2024-513475-41-00 5 2025-02-03 Multiple Sclerosis
• A study to assess how Vaborem® is taking up in the body and tolerated in paediatric patients with serious infections. Recruiting
  2024-514656-32-00 4 2025-01-23 Suspected or confirmed Gram negative infections
• Chronic anticoagulation in end-stage renal disease patients: pharmacocinetics and pharmacodynamic of a reduced dose regimen of rivaroxaban ( … Recruiting
  2023-505733-28-00 4 2025-01-08 Chronic hemodialysis
• EvER-ILD 3 : Evaluation of Efficacy and safety of Rituximab and mycophenolate mofetil combination in patients with Interstitial Lung Disease … Recruiting
  2023-510507-21-00 10 2025-01-08 Intersitial lung disease related to systemic sclerosis
• A Phase 3 efficacy and safety study of fosmanogepix for the treatment of adult participants with candidemia and/or invasive candidiasis. Recruiting
  2022-500455-23-00 5 2024-12-11 Candidemia
• Evaluation of the addition of Everolimus to 177Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical tr … Recruiting
  2023-508400-38-00 4 2024-11-29 meningioma

Showing 49–72 of 208 trials